Return to study ST000138 main page
MB Sample ID: SA007676
Local Sample ID: | PR0608 |
Subject ID: | SU000157 |
Subject Type: | Human |
Subject Species: | Homo sapiens |
Taxonomy ID: | 9606 |
Human Inclusion Criteria: | Participants with a baseline fasting glucose < 100 mg/dl and a fasting glucose ? 100 mg/dl at the end of atenolol treatment are considered to have developed IFG. Participants with a baseline fasting glucose < 100 mg/dl and a fasting glucose that remained < 100 mg/dl at the end of atenolol treatment are considered to have not developed IFG. |
Human Exclusion Criteria: | Participants with a fasting glucose ? 100 mg/dl at baseline are excluded from this study. |
Species Group: | Human |
Select appropriate tab below to view additional metadata details:
Combined analysis:
Analysis ID | AN000220 |
---|---|
Analysis type | MS |
Chromatography type | Reversed phase |
Chromatography system | Agilent 1290 Infinity |
Column | Waters Acquity BEH C18 (100 x 2mm,1.7um) |
MS Type | ESI |
MS instrument type | Triple quadrupole |
MS instrument name | Agilent 6490 QQQ |
Ion Mode | POSITIVE |
Units | uM |
Chromatography:
Chromatography ID: | CH000152 |
Instrument Name: | Agilent 1290 Infinity |
Column Name: | Waters Acquity BEH C18 (100 x 2mm,1.7um) |
Chromatography Type: | Reversed phase |